Retatrutide vs MariTide: Two Drugs, Two Opposite Bets on the Same Receptor

Introduction

The GLP-1 receptor is where every obesity drug in the modern class begins. What comes after GLP-1 is where drug developers have made radically different bets.

Eli Lilly added GIP receptor activation to get tirzepatide — and retatrutide went further, adding glucagon. Novo Nordisk added amylin receptor activity (cagrilintide). But the most surprising development in obesity pharmacology is from Amgen: MariTide, a drug that targets the GIP receptor in the opposite direction of everyone else.

Retatrutide activates GIP receptors. MariTide blocks them.

Both approaches appear to work. That shouldn't be entirely possible under a simple mechanistic model — and the fact that it is tells us something important about how poorly understood GIP biology actually is. This article covers what both drugs are, what the data shows, and why the scientific tension between them is one of the most interesting open questions in metabolic medicine.

Important upfront caveat: This comparison is inherently asymmetric. Retatrutide has completed two Phase 3 trials with 2,784 participants across 68–80 weeks. MariTide has completed Phase 2 with 52-week data. These represent very different levels of evidence — and the numbers are not directly comparable.

The GIP Receptor: What Is It and Why Does It Matter?

GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone released from the gut in response to eating. Its primary roles include stimulating insulin release and modulating fat storage.

What makes GIP pharmacologically interesting is that its effects can be interpreted in two ways depending on which tissues you focus on:

The case for activating GIP (Lilly's view): GIP receptor agonism in the brain reduces food intake and appears to enhance GLP-1's tolerability and efficacy. In adipose tissue, GIP may improve insulin sensitivity. Tirzepatide's dramatically superior efficacy over semaglutide suggests that GIP activation adds real weight loss benefit beyond GLP-1 alone.

The case for blocking GIP (Amgen's view): Human genetic studies show that people with naturally reduced GIP signaling tend to have lower BMI. In adipose tissue specifically, GIP promotes fat storage. Blocking GIP may therefore reduce adipogenesis and the body's drive to store energy as fat.

The fundamental paradox: GIP receptor agonism (tirzepatide) and GIP receptor antagonism (MariTide) both produce meaningful weight loss beyond GLP-1 alone. As study co-author Donna H. Ryan, MD (Pennington Biomedical Research Center), stated at the presentation of MariTide's Phase 2 results: "The fact that there are positive effects here with GIP antagonism, and also with tirzepatide's GIP agonism, isn't fully understood."

This is not a rhetorical deflection. It reflects a genuine gap in the science. Both approaches work. We do not fully understand why.

What Is MariTide?

MariTide (maridebart cafraglutide, formerly AMG 133) is an investigational therapy developed by Amgen. It is structurally different from every other obesity drug in development.

Mechanism: MariTide is a bispecific antibody-peptide conjugate — a monoclonal antibody that blocks GIP receptors, with two GLP-1 receptor agonist peptides chemically attached to it. It simultaneously activates GLP-1 receptors (appetite suppression, slowed gastric emptying) and antagonizes GIP receptors (blocked fat storage signaling).

Structure: Because it is built on an antibody scaffold, MariTide has a half-life of approximately 21 days — approximately three times longer than weekly GLP-1 peptides. This allows monthly or less frequent dosing.

Dosing: In the Phase 2 trial, MariTide was administered monthly. Phase 3 (MARITIME) is evaluating dosing from monthly to potentially quarterly.

Manufacturer: Amgen (NASDAQ: AMGN). Phase 3 MARITIME trials are actively enrolling as of 2025–2026.

The Phase 2 Data: What MariTide Actually Showed

The primary Phase 2 results were published in the New England Journal of Medicine on June 23, 2025 (Jastreboff AM, Ryan DH, Bays HE, et al.), with full results presented at the ADA 85th Scientific Sessions.

Obesity cohort (without T2D), 52 weeks:

Note: Part 2 of the Phase 2 study is ongoing, investigating continued weight loss beyond 52 weeks, durability after discontinuation, and weight maintenance through reduced dosing frequency.

Obesity + T2D cohort, 52 weeks:

Additional findings:

• No association with bone mineral density changes ✅
• GI side effects (nausea, vomiting, constipation) were the most common — but predominantly mild, transient, primarily associated with the first dose, and substantially reduced with dose escalation

Retatrutide: Phase 3 Reference Data

The Direct Mechanism Comparison

Why the Weight Loss Numbers Are Not Directly Comparable

The most common mistake in covering these two drugs is placing their weight loss figures side by side without acknowledging the evidence gap.

Retatrutide: 28.3–28.7% comes from two completed Phase 3 registrational trials with 2,784 participants across 68–80 weeks. These are the numbers that will form the FDA NDA package.

MariTide: "Up to ~20%" comes from a Phase 2 trial of 592 adults at 52 weeks. The full Phase 2 published results showed ITT weight loss of 12.3–16.2% across dose groups, with "up to ~20%" representing the efficacy estimand at the highest dose. Phase 3 data does not yet exist.

No plateau was observed at 52 weeks in the MariTide trial — meaning weight was still declining when the primary endpoint was measured. How much additional loss would accumulate at 68 or 80 weeks is unknown. It is possible MariTide's Phase 3 final weight loss will be meaningfully higher than 20%. It is also possible that differences in population, trial design, and dose will result in numbers lower than retatrutide's Phase 3 data. We simply do not know.

For context: retatrutide's Phase 2 at 48 weeks showed 24.2% (efficacy estimand) — its Phase 3 at 68–80 weeks showed 28.3–28.7%. The extra 20 weeks produced meaningful additional loss. MariTide's Phase 2 at 52 weeks, still not at plateau, may follow a similar extension trajectory.

Dosing: MariTide's Clearest Potential Advantage

If MariTide delivers comparable weight loss to retatrutide in Phase 3, monthly — or potentially quarterly — dosing is a genuine clinical differentiator.

Weekly injections are manageable for most patients, but adherence over years of treatment is a real challenge. A drug that can be administered monthly or less frequently while maintaining efficacy could meaningfully improve long-term outcomes simply by reducing the adherence burden.

Phase 3 MARITIME will evaluate whether monthly and less-frequent dosing schedules maintain the efficacy seen in Phase 2. The antibody scaffold's 21-day half-life gives Amgen theoretical grounds for quarterly dosing.

One practical concern to note: MariTide's Phase 2 used doses up to 420 mg (approximately 6 mL injection), which Amgen recognized as a practical barrier. Phase 3 MARITIME addresses this directly: using a PK-LDI (Low Dose Initiation) strategy with a starting dose of 21 mg escalating to a target of 70 mg — substantially smaller volume than Phase 2 and closer to the injection size of existing GLP-1 medications. Dose escalation with lower starting doses also substantially improved GI tolerability without compromising efficacy.

Where Each Drug Stands Today (July 2026)

Retatrutide:Two Phase 3 trials complete (TRIUMPH-1, TRIUMPH-4). TRANSCEND-T2D-1 published in The Lancet, June 2026. TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obesity + CVD) ongoing. NDA submission expected Q4 2026. FDA approval projected late 2027. Commercial launch: Q1–Q2 2028.

MariTide:Phase 2 complete, published NEJM June 23, 2025. Phase 3 MARITIME chronic weight management trials actively enrolling. Additional Phase 3 studies in ASCVD, heart failure, and OSA initiated in 2025. FDA submission timeline: no announced date. Earliest realistic availability: 2029–2030.

Retatrutide is approximately 2–3 years ahead of MariTide on the regulatory timeline based on current information.

The Scientific Question That Remains Open

The GIP paradox at the heart of this comparison does not yet have a clean resolution. Both tirzepatide (GIP agonist) and MariTide (GIP antagonist) produce weight loss that exceeds GLP-1 alone. Both are in Phase 3 development.

Several hypotheses attempt to explain this:

Tissue-specific effects: GIP may have different effects in the brain (where antagonism may reduce reward signaling) versus adipose tissue (where agonism may improve insulin sensitivity). The net effect of each approach depends on which tissue is dominant for weight regulation.

Receptor distribution: GIP receptors are expressed differently across tissues. A drug that primarily modulates central GIP signaling (antagonism may work there) versus peripheral GIP signaling (agonism may work there) could explain why both approaches produce benefit through different dominant pathways.

Complementary mechanisms: MariTide adds GLP-1 agonism on top of GIPR antagonism — the combination may work through the GLP-1 component more than the GIP component, with GIPR antagonism adding a modest incremental effect through a different pathway.

None of these explanations has been definitively established. The GIP receptor remains one of the most contested targets in pharmacology.

For a comparison with another next-generation obesity drug, see our retatrutide vs amycretin comparison.

Who Might Eventually Prefer MariTide?

Based on what Phase 2 shows — and subject to Phase 3 confirmation — MariTide's potential profile could suit:

Patients for whom weekly injection frequency is a genuine adherence barrier. Monthly or quarterly dosing may represent a quality-of-life improvement that maintains outcomes over years that weekly dosing might not.

Patients who achieved inadequate results on tirzepatide and want a mechanistically distinct option. If GIP agonism didn't help enough in their case, GIP antagonism might engage different pathways.

Patients in whom bone density changes are a concern — Phase 2 showed no association with bone mineral density reduction, which contrasts with concerns about rapid weight loss and bone health.

None of these profiles are defined by Phase 2 data. Phase 3 will determine whether MariTide's efficacy, safety, and practical advantages hold at scale.

Conclusion

Retatrutide and MariTide represent two of the most scientifically interesting drugs in obesity development. They target the same GIP receptor through opposite mechanisms, both show meaningful weight loss, and both are based on the recognition that GLP-1 alone leaves substantial efficacy on the table.

What distinguishes them today:

Retatrutide has Phase 3 data, an NDA on the way, and a launch timeline of 2028. MariTide has compelling Phase 2 data, monthly dosing that nobody else in the class offers, and Phase 3 results that will determine whether it can compete on efficacy at longer durations.

The honest comparison: retatrutide is currently ahead on every measurable dimension — evidence strength, regulatory timeline, weight loss magnitude confirmed in Phase 3. MariTide is the more innovative molecule structurally, with a dosing advantage that could matter clinically if Phase 3 confirms its efficacy.

Whether GIP should be activated or blocked is a question obesity medicine will spend the next several years answering.

Sources

• Jastreboff AM, Ryan DH, Bays HE, et al. "Once-monthly maridebart cafraglutide for the treatment of obesity — a phase 2 trial." New England Journal of Medicine. Published online June 23, 2025. doi:10.1056/NEJMoa...
• Amgen press release: "Amgen Announces Robust Weight Loss With MariTide in People Living With Obesity or Overweight at 52 Weeks in a Phase 2 Study." November 26, 2024.
• Amgen press release: "Results from Amgen's Phase 2 Obesity Study of Monthly MariTide Presented at the American Diabetes Association 85th Scientific Sessions." June 23, 2025.
• Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine, 2023;389:514–526.
• Eli Lilly press release: TRIUMPH-1 Phase 3 topline results. May 21, 2026.
• Eli Lilly press release: TRIUMPH-4 Phase 3 topline results. December 11, 2025.
• Hammoud R, Drucker DJ. "Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP-1." Nature Reviews Endocrinology, 2023.